Search
Ceftobiprole
go.drugbank.com/drugs/DB04918ApprovedWithdrawn[L50467] It received its first approval in Canada in October 2017 for use in certain patients with bacterial pneumonia,[L50472] and was subsequently approved in the United States with additional indications … for skin and skin structure infections and bacteremia in April 2024.
Acenocoumarol
go.drugbank.com/drugs/DB01418ApprovedInvestigationalThis prevents carboxylation of vitamin K-dependent clotting factors, II, VII, IX and X, and interferes with coagulation. … Acenocoumarol is a coumarin derivative used as an anticoagulant. Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase.
Tafenoquine
go.drugbank.com/drugs/DB06608ApprovedInvestigational[A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria. … [A35677] It was FDA approved on July 20, 2018.[L3770]
Aceclofenac
go.drugbank.com/drugs/DB06736ApprovedIt is a more commonly prescribed drug in Europe. … In 1991, aceclofenac was developed as an analog of a commonly prescribed NSAID, [DB00586], via chemical modification in effort to improve the gastrointestinal tolerability of the drug.
Dasiglucagon
go.drugbank.com/drugs/DB15226Approved[L39195] In March 2021, the FDA approved dasiglucagon to treat severe hypoglycemia in patients six years and older with diabetes. It is available as a subcutaneous injection marketed as ZEGALOGUE. … Although it tends to be more common in type 1 diabetes mellitus, occurring in about 22% to 46% of patients annually, about 7% to 25% of patients with type 2 diabetes mellitus treated with insulin experience
Vanzacaftor
go.drugbank.com/drugs/DB18373ApprovedInvestigationalIt is used alongside other CFTR correctors and CFTR potentiators to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis. … [L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor
JPC-3210
go.drugbank.com/drugs/DB15609ExperimentalIt is an erythrocytic schizonticide with potent in vitro antimalarial activity against multidrug-resistant _Plasmodium falciparum_ lines, low cytotoxicity, potent in vivo efficacy against murine malaria … JPC-3210 is a potent antimalarial agent.
Triamterene
go.drugbank.com/drugs/DB00384ApprovedIt works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. … [L6166] It is also found in a combination product with hydrochlorothiazide that is used for the management of hypertension or treatment of edema in patients who develop hypokalemia on hydrochlorothiazide
Urea C-14
go.drugbank.com/drugs/DB09513ApprovedInvestigationalAs the urease enzyme is not present in mammalian cells, the presence of urease (and the products of urea cleavage) in the stomach is evidence that H. pylori bacteria are present. … If gastric urease from H. pylori is present, urea is split to form CO2 and NH3 at the interface between the gastric epithelium and lumen and 14CO2 is absorbed into the blood and exhaled in the breath.
Ceftobiprole medocaril
go.drugbank.com/drugs/DB14733Approved[L50467] It received its first approval in Canada in October 2017 for use in certain patients with bacterial pneumonia,[L50472] and was subsequently approved in the United States with additional indications … for skin and skin structure infections and bacteremia in April 2024.
Products: Zevtera 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung